• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

ZM-447439 Trihydrate

Product ID Z4900
Cas No. 331771-20-1
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $88.60 In stock
5 mg $165.50 In stock
25 mg $636.70 Please Inquire
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

ZM-447439 inhibits aurora kinases A and B (AurA, AurB), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer activity, inducing hyperploidy and apoptosis in osteosarcoma cells and inhibiting growth in mesothelioma cells. ZM-447439 also induces apoptosis and inhibits expression of AurB and H3-P protein in cervical cancer cells, suppressing growth and survival.

Product Info

Cas No.

331771-20-1

Purity

≥99%

Formula

C29H31N5O4 • 3H2O

Formula Wt.

567.63

IUPAC Name

N-[4-[[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino]phenyl]benzamide

Solubility

DMSO 103 mg/mL (200.54 mM) Water Insoluble Ethanol Insoluble

Appearance

White to Off-white Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

Z4900 MSDS PDF

Info Sheet

Z4900 Info Sheet PDF

References

Tavanti E, Sero V, Vella S, et al. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer. 2013 Nov 12;109(10):2607-18. PMID: 24129234.

Baldini E, Tuccilli C, Prinzi N, et al. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity. J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):705-15. PMID: 24152827.

Crispi S, Fagliarone C, Biroccio A, et al. Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer. 2010 Dec;70(3):271-9. PMID: 20371132.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only